Comparing Black Titan (NASDAQ:BTTC) & Xperi (NYSE:XPER)

Black Titan (NASDAQ:BTTC) and Xperi (NYSE:XPER) are both small-cap services companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Black Titan and Xperi”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Titan	$180,000.00	74.74	-$4.71 million	($2.95)	-0.50
Xperi	$448.11 million	0.60	-$56.34 million	($1.23)	-4.63

Black Titan has higher earnings, but lower revenue than Xperi. Xperi is trading at a lower price-to-earnings ratio than Black Titan, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Black Titan and Xperi, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Xperi	2	0	2	0	2.00

Xperi has a consensus target price of $11.00, suggesting a potential upside of 93.15%. Given Xperi’s stronger consensus rating and higher possible upside, analysts clearly believe Xperi is more favorable than Black Titan.

Insider and Institutional Ownership

94.3% of Xperi shares are held by institutional investors. 0.7% of Black Titan shares are held by company insiders. Comparatively, 3.2% of Xperi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Black Titan and Xperi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Xperi	-12.57%	-0.73%	-0.49%

Risk & Volatility

Black Titan has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Xperi has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

Summary

Xperi beats Black Titan on 9 of the 14 factors compared between the two stocks.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

About Xperi

Xperi Holding Corporation, together with its subsidiaries, operates as a consumer and entertainment product/solutions licensing company worldwide. It operates through two segments, Product, and Intellectual Property Licensing. The company invents, develops, and delivers various technologies. It licenses audio, digital radio, imaging, edge-based machine learning, and multi-channel video user experience solutions to consumer electronics customers, automotive manufacturers, or supply chain partners. The company also provides licensing to multichannel video programming distributors, OTT video service providers, consumer electronics manufacturers, social media, and other new media companies in media industry; and memory, sensors, RF component, and foundry companies in semiconductor industry. It provides its technologies under the DTS, HD Radio, IMAX Enhanced, Invensas, TiVo, and Perceive brands. The company is headquartered in San Jose, California.